These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15330974)

  • 1. Cognition-enhancing drugs.
    Mehlman MJ
    Milbank Q; 2004; 82(3):483-506, table of contents. PubMed ID: 15330974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Just treat, or enhance?
    Kennedy D
    Science; 2004 Apr; 304(5667):17. PubMed ID: 15060288
    [No Abstract]   [Full Text] [Related]  

  • 3. Expectations regarding cognitive enhancement create substantial challenges.
    Racine E; Forlini C
    J Med Ethics; 2009 Aug; 35(8):469-70. PubMed ID: 19644002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing cognition in the intellectually intact.
    Whitehouse PJ; Juengst E; Mehlman M; Murray TH
    Hastings Cent Rep; 1997; 27(3):14-22. PubMed ID: 9219019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RU-486: legal and policy issues confronting the Food and Drug Administration.
    Muhl C
    J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine introduced in Europe.
    Am J Alzheimers Dis Other Demen; 2001; 16(1):8. PubMed ID: 11416951
    [No Abstract]   [Full Text] [Related]  

  • 8. How the FDA forgot the evidence: the case of donepezil 23 mg.
    Schwartz LM; Woloshin S
    BMJ; 2012 Mar; 344():e1086. PubMed ID: 22442352
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
    Daemmrich A; Krucken G
    Sci Cult (Lond); 2000 Dec; 9(4):505-34. PubMed ID: 15988846
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race-specific drugs: regulatory trends and public policy.
    Winickoff DE; Obasogie OK
    Trends Pharmacol Sci; 2008 Jun; 29(6):277-9. PubMed ID: 18453000
    [No Abstract]   [Full Text] [Related]  

  • 12. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 13. Side effects of approved antidementives.
    Mimica N; Presecki P
    Psychiatr Danub; 2009 Mar; 21(1):108-13. PubMed ID: 19270633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social policy and drug safety.
    Tilson HH
    Clin Geriatr Med; 1986 Feb; 2(1):165-80. PubMed ID: 3513933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piracetam: a novel therapy for autism?
    Paczynski M
    J Autism Dev Disord; 1997 Oct; 27(5):628-30. PubMed ID: 9403377
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA, off-label use, and informed consent: debunking myths and misconceptions.
    Beck JM; Azari ED
    Food Drug Law J; 1998; 53(1):71-104. PubMed ID: 11795338
    [No Abstract]   [Full Text] [Related]  

  • 17. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive enhancement: promises and perils.
    Hyman SE
    Neuron; 2011 Feb; 69(4):595-8. PubMed ID: 21338872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting.
    Binder GM
    Curr Opin Biotechnol; 1999 Jun; 10(3):303-6. PubMed ID: 10361077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining reports and policies on cognitive enhancement: approaches, rationale, and recommendations.
    Outram SM; Racine E
    Account Res; 2011; 18(5):323-41. PubMed ID: 21916740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.